机构:[1]Beijing University of Chinese Medicine, Chaoyang, Beijing, China.[2]Shenzhen Hospital, Beijing University of Chinese Medicine, Guangdong, China.北京大学深圳医院深圳医学信息中心[3]Cardiology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Dongcheng, Beijing, China.
Hyperlipidemia is one of the independent risk factors for the onset of coronary heart disease (CHD), and our aim is to construct a coronary risk prediction model for patients with hyperlipidemia based on carotid ultrasound in combination with other risk factors.The nomogram risk prediction model is based on a retrospective study on 820 patients with hyperlipidemia. The predictive accuracy and discriminative ability of the nomogram were determined by receiver operating characteristic (ROC) curves and calibration curves. The results were validated using bootstrap resampling and a prospective study on 39 patients with hyperlipidemia accepted at consenting institutions from 2021 to 2022.In the modeling cohort, 820 patients were included. A total of 33 variables were included in univariate logistic regression. On multivariate analysis of the modeling cohort, independent factors for survival were sex, age, hypertension, plaque score, LVEF, PLT, and HbAlc, which were all selected into the nomogram. The calibration curve for probability of survival showed good agreement between prediction by nomogram and actual observation. The area under the curve (AUC) of the nomogram model was 0.881 (95% CI 0.858∼0.905), with a sensitivity of 79% and a specificity of 81.7%. In the validation cohort, the AUC was 0.75, 95% CI (0.602∼0.906). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of this model were 54.16%, 80%, 81.25%, 52.17% and 64.1%. This model showed a good fitting and calibration and positive net benefits in decision curve analysis.A nomogram model for CHD risk in patients with hyperlipidemia was developed and validated using 7 predictors, which may have potential application value in clinical risk assessment, decision-making, and individualized treatment associated with CHD.
基金:
The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This study
was supported by The National Key Research and Development Program
of China, Grant/Award Number: 2017YFC1700206.
第一作者机构:[1]Beijing University of Chinese Medicine, Chaoyang, Beijing, China.[2]Shenzhen Hospital, Beijing University of Chinese Medicine, Guangdong, China.
通讯作者:
通讯机构:[3]Cardiology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, Dongcheng, Beijing, China.[*1]Cardiology Department, Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 5 Haiyuncang, Dongcheng District, Beijing 100700, China.
推荐引用方式(GB/T 7714):
Zeng Yuanyuan,Zhao Jing,Zhang Jingfang,et al.Development of a Nomogram That Predicts the Risk of Coronary Heart Disease in Patients With Hyperlipidemia[J].JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS.2023,28:doi:10.1177/10742484231167754.
APA:
Zeng Yuanyuan,Zhao Jing,Zhang Jingfang,Yao Tingting,Weng Jieqiong...&Shen Xiaoxu.(2023).Development of a Nomogram That Predicts the Risk of Coronary Heart Disease in Patients With Hyperlipidemia.JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS,28,
MLA:
Zeng Yuanyuan,et al."Development of a Nomogram That Predicts the Risk of Coronary Heart Disease in Patients With Hyperlipidemia".JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS 28.(2023)